These tests are mainly used as rationales for treatment decisions, for example to detect activating mutations in the Epidermal Growth Factor Receptor (EGFR) that can be treated by administering Osimertinib in patient with NSCLC (18). This evidence concerns the gene EGFR and non-small cell lung carcinoma.